Reply-Letter to the editor: Cardiometabolic benefits of Lacticaseibacillus paracasei 8700:2: A randomized double-blind placebo-controlled trial

Clin Nutr. 2024 Jan;43(1):300-301. doi: 10.1016/j.clnu.2023.11.016. Epub 2023 Nov 25.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cardiovascular Diseases*
  • Double-Blind Method
  • Humans
  • Lacticaseibacillus paracasei*
  • Probiotics* / therapeutic use
  • Randomized Controlled Trials as Topic